Impact of Treatment Intensity on Quality of Life in Patients With Metastatic Testicular Cancer

Testicular cancer (TC) is the most common malignancy in young men and is highly curable with platinum-based chemotherapy. With growing survivorship rates, treatment-related symptom burden and quality of life (QoL) have become increasingly important. This study evaluates the impact of different TC treatments on symptom burden and QoL. MATERIAL AND

No direct change to audiology practice is warranted; however, audiologists treating patients on platinum-based chemotherapy should remain vigilant for monitoring ototoxicity, as treatment intensity may influence its severity.

Platinum-based chemotherapy is a known cause of ototoxicity, and understanding how treatment intensity modulates this risk could inform audiological monitoring protocols for oncology patients.

1. 01Study examines QoL outcomes in metastatic testicular cancer patients on platinum-based chemotherapy.
2. 02Ototoxicity (medication-related hearing damage) is a recognised side effect of platinum compounds.
3. 03Higher treatment intensity may be associated with greater burden of side effects including hearing loss.
4. 04Findings have peripheral relevance to audiologists involved in ototoxicity monitoring in oncology settings.
5. 05Full audiology-specific outcome data not the primary focus of the study.

PMID

42338403

DOI

10.1111/andr.70295.

Journal

Andrology

Publication type

research_article

Evidence level

2b

Population

Patients with metastatic testicular cancer receiving platinum-based chemotherapy

Intervention

Varying intensities of platinum-based chemotherapy

Comparator

Lower vs. higher treatment intensity regimens